Intelligence directory
Browse A–Z
Browse LongevityNext’s research articles, interventions, clinical trials and biomarker records in one alphabetical directory.
Leading punctuation is ignored. Numbers come first; accented letters and other scripts appear under Other.
Records
34 eligible records · Page 1 of 2
- Abu Dhabi Longevity Clinics: What Current Official Sources ShowArticle
- Aging Biomarkers Compared: What Each Measure Captures—and What It Cannot ProveArticle
- Aging Trial Endpoints: A Role-Based Interpretation Framework Without False EquivalenceArticle
- Autophagy as a Drug Target: Separating Flux, Target Engagement and Clinical BenefitArticle
- Beyond the Snapshot: When Repeated Measurements Improve Aging-Biomarker EvidenceArticle
- Canine Longevity Drugs: What Conditional Approval Would—and Would Not—EstablishArticle
- Chronic Inflammation in Aging: Evidence Map, Measures, and Intervention LimitsArticle
- Clinics, Labs and Data: How to Evaluate an Evidenced Healthcare Roll-UpArticle
- Diagnostics, Canine Therapeutics and Drug Discovery: Three Different Business RisksArticle
- Digital Twins, Aging Clocks and AI Drug Discovery: Three Claims, Three Validation TestsArticle
- Disease, Wellness and Longevity Claims: The US Evidence and Scope BoundaryArticle
- Do We Need Aging Clocks—or Better Answers to Specific Health Questions?Article
- Evidence-Based Longevity Clinics: A Framework for Evaluating Services, Claims, and TransparencyArticle
- Extracellular Matrix and Aging: From Tissue Mechanics to Translational EvidenceArticle
- From 9 to 12 Hallmarks: What the Aging Framework Explains—and What It Does NotArticle
- From Preclinical Promise to Human Evidence: How to Read a Longevity Translation ClaimArticle
- GLP-1 Therapies and Longevity Claims: What Human Outcomes Support—and What Remains UntestedArticle
- Longevity Capital in 2026: Disclosed Deals, Different Instruments, and the Limits of the EvidenceArticle
- Longevity Clinic Registries: The Minimum Evidence Needed to Interpret OutcomesArticle
- Longevity Trial Endpoints: Choosing Between Clinical Outcomes, Function and BiomarkersArticle
- Model Organisms in Longevity Research: What Transfers—and What Does NotArticle
- Negative Longevity Trials: How to Read a Missed Endpoint Without Losing the EvidenceArticle
- NewLimit’s Series C: What Disclosed Capital and Company Milestones Actually ShowArticle
- Partial Reprogramming in Human Testing: Programme Milestones, Safety Questions, and Evidence GapsArticle